FDA Approves Alprolix for Hemophilia B

Publication
Article
Hemophilia ReportsAugust 2014
Volume 1
Issue 2

Prophylactic treatment for hemophilia B requires fewer injections than current options.

Alprolix [Coagulation Factor IX (Recombinant), Fc Fusion Protein], indicated for the prevention or reduction of bleeding episodes for patients with hemophilia B, was FDA-approved on March 28, 2014. It is the first treatment for hemophilia B that has prolonged circulation in the body, requiring less frequent injections. Alprolix can be administered for routine prophylaxis once every week or once every 10 days, depending on the dose.

“The hemophilia community is excited about new therapy options for the prophylactic management of hemophilia B,” said Val Bias, chief executive officer of the National Hemophilia Foundation. “This approval is a significant step forward because it provides an important new option and expanded choice for the hemophilia B community.”

A clinical trial that enrolled 123 Hemophilia B patients, ages 12-71, evaluated the safety and efficacy of Alprolix for prophylaxis and on-demand treatment. Alprolix was shown to be effective in treating and preventing bleeding episodes and the study did not reveal any safety issues.

Alprolix, manufactured by Biogen Idec, Inc., Cambridge, Mass, was designated as an orphan drug because hemophilia B is a rare disease, affecting about 4,000 people in the United States. It is priced at $2.85 per unit, which is more than twice the price of Benefix, an older treatment for hemophilia B that is priced at $1.19 per unit. Alprolix is dosed less frequently than Benefix, however, and prices vary widely based on the patient’s weight and how severe their disease is.

Related Videos
Getting Black Men Involved in Their Health Care, Clinical Research
Patient Involvement in Advanced HF Treatment, with Ashley Malliett, DMSc, MPAS, PA-C
Aaron Henry, PA-C, MSHS: Regaining Black Male Patient Trust in the Doctor's Office
What Should the American Academy of Physician Associates Focus on in 2025?
© 2024 MJH Life Sciences

All rights reserved.